Sanofi Pas­teur re­leases FluQuadri vac­cine

BioSpectrum (India) - - COMPANY NEWS -

Sanofi Pas­teur, the vac­cine di­vi­sion of Sanofi, re­cently an­nounced the launch of its 4-strain in­fluenza vac­cine FluQuadri in In­dia. FluQuadri will be In­dia’s first quadri­va­lent vac­cine to pro­vide broader pro­tec­tion against in­fluenza to pop­u­la­tion above 3 years of age. Cur­rently, the ma­jor­ity of sea­sonal in­fluenza vac­cines are triva­lent, mean­ing that they pro­tect against: two A strains and one sin­gle B lin­eage (B/Vic­to­ria or B/Ya­m­a­gata) of In­fluenza virus. How­ever, over the re­cent flu sea­sons, co-cir­cu­la­tion of both B lin­eages has been con­sis­tently ob­served, mak­ing it dif­fi­cult for the World Health Or­ga­ni­za­tion (WHO) to rec­om­mend which B strain should be in­cor­po­rated in triva­lent in­fluenza vac­cines. Given the change in epi­demi­ol­ogy, quadri­va­lent vac­ci­na­tion rep­re­sent the next log­i­cal step to an ad­vanced level of pro­tec­tion. The WHO in­cludes quadri­va­lent in­fluenza vac­cines in its rec­om­men­da­tions, stat­ing that Quadri­va­lent in­fluenza vac­cines that could po­ten­tially pro­vide wider pro­tec­tion against in­fluenza B viruses are be­com­ing avail­able and rec­om­men­da­tions should not be lim­ited to triva­lent vac­cine.

Newspapers in English

Newspapers from India

© PressReader. All rights reserved.